Agilus Diagnostics launches Idylla System for rapid detection of cancer mutations

Agilus Diagnostics, subsidiary of Fortis Healthcare, has launched the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling rapid detection of cancer-related genetic mutations within 2.5 to 3 hours.

The launch marks a significant advancement in accelerating clinical decision-making and expanding access to precision oncology in India.

The Idylla system is a fully integrated, cartridge-based molecular testing platform that combines sample processing, nucleic acid extraction, amplification and detection into a single automated workflow. By minimising manual intervention and pre-analytical variability, the system delivers highly accurate and reproducible results in a significantly shorter timeframe compared to conventional molecular testing methods, which can take several days.

This capability is particularly critical in oncology, where timely identification of actionable biomarkers plays a decisive role in guiding targeted therapies. The platform enables rapid detection of clinically relevant mutations, including:

• EGFR – commonly associated with lung cancer in Indian and Asian populations
• KRAS and NRAS – key markers in colorectal and pancreatic cancers
• BRAF – present across multiple tumor types, including melanoma and colorectal cancer

Additionally, the system supports detection of emerging biomarkers such as MSI (Microsatellite Instability) and IDH1/IDH2, which are increasingly important in determining eligibility for advanced targeted and immunotherapies.

With this addition, Agilus Diagnostics further enhances its integrated oncology diagnostics ecosystem, enabling faster, more efficient biomarker-driven treatment pathways and improved access to advanced cancer care.